-
1.发明申请USE OF TP MODULATORS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS IN ASPIRIN SENSITIVE AND OTHER POPULATIONS 审中-公开使用TP调节剂治疗腹泻敏感型和其他人群中的心血管疾病公开(公告)号：US20090012115A1
公开(公告)日：2009-01-08
申请号：US12114642
申请日：2008-05-02
IPC分类号： A61K31/4365 , A61K31/422 , A61K31/4406 , A61K31/18 , A61K31/444 , A61K31/192 , A61K31/403 , A61P9/00
CPC分类号： A61K31/422 , A61K31/20 , A61K31/405 , A61K31/4406 , A61K31/444 , A61K45/06
摘要： The present invention provides methods and compositions useful in the treatment or prevention of cardiovascular disorders in individuals for whom therapy with a COX-1 enzyme inhibitor is not feasible due to sensitivity, intolerance, or resistance to the inhibitor. Additionally, the invention provides methods of treating cardiovascular disorders in an individual who is receiving a therapeutically effective dose of a TP modulator and is instructed or advised to avoid and/or not to take aspirin or another COX-1 inhibitor.
摘要翻译： 本发明提供了用于治疗或预防由于敏感性，不耐受性或对抑制剂的抗性而使用COX-1酶抑制剂治疗不可行的个体的心血管疾病的方法和组合物。 另外，本发明提供治疗正在接受治疗有效剂量的TP调节剂的个体的心血管疾病的方法，并被指示或建议避免和/或不服用阿司匹林或另一种COX-1抑制剂。
-
公开(公告)号：US08153590B2
公开(公告)日：2012-04-10
申请号：US12239651
申请日：2008-09-26
申请人： Genmin Lu , David R. Phillips , Patrick Andre , Uma Sinha
发明人： Genmin Lu , David R. Phillips , Patrick Andre , Uma Sinha
IPC分类号： A61K35/14
CPC分类号： A61K38/4846 , A61K38/00 , A61K38/4826 , A61K38/4833 , A61K38/4853 , A61K39/00 , A61K47/60 , C07K14/435 , C12N9/6432 , C12Y304/21006
摘要： The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
摘要翻译： 本发明涉及靶向因子Xa的抗凝剂的解毒剂。 解毒剂是与因子Xa抑制剂结合的因子Xa蛋白衍生物，从而基本上中和它们，但不组装到凝血酶原酶复合物中。 本文所述的衍生物缺乏或具有降低的内在凝结剂活性。 本文公开了在目前正在进行使用因子Xa抑制剂进行抗凝治疗的患者中停止或预防出血的方法。
-
3.发明授权Device and methods for identifying and treating aspirin non-responsive patients 失效用于鉴定和治疗阿司匹林非反应性患者的装置和方法公开(公告)号：US07785891B2
公开(公告)日：2010-08-31
申请号：US12037012
申请日：2008-02-25
CPC分类号： G01N33/9486 , G01N33/86
摘要： The present invention relates to methods and compositions for identifying and treating subjects in need of antithrombotic therapies but who are not responsive to aspirin.
摘要翻译： 本发明涉及用于鉴定和治疗需要抗血栓治疗但是对阿司匹林不敏感的受试者的方法和组合物。
-
公开(公告)号：US08470357B2
公开(公告)日：2013-06-25
申请号：US13253899
申请日：2011-10-05
申请人： Patrick Andre , David R. Phillips , Charles Homcy
发明人： Patrick Andre , David R. Phillips , Charles Homcy
IPC分类号： A61F2/02
CPC分类号： A61K31/473 , A61K31/4745 , A61K31/52 , A61L27/34 , A61L27/54 , A61L29/085 , A61L29/16 , A61L2300/434
摘要： The present invention provides novel compositions and methods for inhibiting restenosis, thrombosis, and/or inflammation in a patient undergoing a vascular intervention. More particularly, the present invention provides intravascular devices coated with one or more spleen tyrosine kinase (Syk) inhibitors. Methods for inhibiting restenosis, thrombosis, and/or inflammation in a patient by treatment with such intravascular devices are also provided. In addition, the present invention provides methods for treating sickle cell disease using Syk inhibitors.
摘要翻译： 本发明提供了用于在经历血管干预的患者中抑制再狭窄，血栓形成和/或炎症的新型组合物和方法。 更具体地，本发明提供涂覆有一种或多种脾脏酪氨酸激酶（Syk）抑制剂的血管内装置。 还提供了通过用这种血管内装置治疗来抑制患者再狭窄，血栓形成和/或炎症的方法。 此外，本发明提供了使用Syk抑制剂治疗镰状细胞病的方法。
-
公开(公告)号：US20090098119A1
公开(公告)日：2009-04-16
申请号：US12239651
申请日：2008-09-26
申请人： Genmin Lu , David R. Phillips , Patrick Andre , Uma Sinha
发明人： Genmin Lu , David R. Phillips , Patrick Andre , Uma Sinha
IPC分类号： A61K38/36 , A61P7/02 , A61K39/395 , A61K47/48 , A61K31/715 , A61K31/727 , A61K31/5377 , A61K31/4545 , C07K14/00 , C07H21/00 , C07K16/00 , C12P21/00 , C12N5/10
CPC分类号： A61K38/4846 , A61K38/00 , A61K38/4826 , A61K38/4833 , A61K38/4853 , A61K39/00 , A61K47/60 , C07K14/435 , C12N9/6432 , C12Y304/21006
摘要： The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
摘要翻译： 本发明涉及靶向因子Xa的抗凝剂的解毒剂。 解毒剂是与因子Xa抑制剂结合的因子Xa蛋白衍生物，从而基本上中和它们，但不组装到凝血酶原酶复合物中。 本文所述的衍生物缺乏或具有降低的内在凝结剂活性。 本文公开了在目前正在进行使用因子Xa抑制剂进行抗凝治疗的患者中停止或预防出血的方法。
-
6.发明申请INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR 审中-公开直接作用和可逆的P2Y12抑制剂的口服和口服剂量公开(公告)号：US20090048216A1
公开(公告)日：2009-02-19
申请号：US12114630
申请日：2008-05-02
申请人： Daniel D. Gretler , Pamela B. Conley , Patrick Andre , Athiwat Hutchaleelaha , David R. Phillips , Anjali Pandey , Robert M. Scarborough , Caroll Scarborough , Wolin Huang
发明人： Daniel D. Gretler , Pamela B. Conley , Patrick Andre , Athiwat Hutchaleelaha , David R. Phillips , Anjali Pandey , Robert M. Scarborough , Caroll Scarborough , Wolin Huang
IPC分类号： A61K31/517 , A61K31/60 , A61P9/00
CPC分类号： A61K31/517 , A61K31/216 , A61K2300/00
摘要： The invention provides methods and compositions for rapid and reversible inhibition of platelet aggregation in human subjects in need thereof by administering compounds of the formula: alone or in combination with a second agent which can be aspirin or a thrombolytic agent.
摘要翻译： 本发明提供了通过施用下式的化合物单独或与可以是阿司匹林或溶栓剂的第二药剂组合来快速和可逆地抑制有需要的人受试者血小板聚集的方法和组合物。
-
7.发明授权Device and methods for identifying and treating aspirin non-responsive patients 失效用于鉴定和治疗阿司匹林非反应性患者的装置和方法公开(公告)号：US07358091B2
公开(公告)日：2008-04-15
申请号：US11304054
申请日：2005-12-14
IPC分类号： G01N33/86
CPC分类号： G01N33/9486 , G01N33/86
摘要： The present invention relates to methods and compositions for identifying and treating subjects in need of antithrombotic therapies but who are not responsive to aspirin.
摘要翻译： 本发明涉及用于鉴定和治疗需要抗血栓治疗但是对阿司匹林不敏感的受试者的方法和组合物。
-
8.发明申请INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR 审中-公开直接作用和可逆的P2Y12抑制剂的口服和口服剂量公开(公告)号：US20120009172A1
公开(公告)日：2012-01-12
申请号：US13235305
申请日：2011-09-16
申请人： Daniel D. Gretler , Pamela B. Conley , Patrick Andre , Athiwat Hutchaleelaha , David R. Phillips , Anjali Pandey , Robert M. Scarborough , Carroll Anna Crew Scarborough , Wolin Huang
发明人： Daniel D. Gretler , Pamela B. Conley , Patrick Andre , Athiwat Hutchaleelaha , David R. Phillips , Anjali Pandey , Robert M. Scarborough , Carroll Anna Crew Scarborough , Wolin Huang
IPC分类号： A61K38/45 , A61K38/48 , A61P9/00 , A61K31/517 , C07D409/12 , A61P7/00 , A61K38/46 , A61K31/60
CPC分类号： A61K31/517 , A61K31/216 , A61K2300/00
摘要： The invention provides methods and compositions for rapid and reversible inhibition of platelet aggregation in human subjects in need thereof by administering compounds of the formula: alone or in combination with a second agent which can be aspirin or a thrombolytic agent.
摘要翻译： 本发明提供了通过施用下式的化合物单独或与可以是阿司匹林或溶栓剂的第二药剂组合来快速和可逆地抑制有需要的人受试者血小板聚集的方法和组合物。
-
公开(公告)号：US08057815B2
公开(公告)日：2011-11-15
申请号：US11107324
申请日：2005-04-15
申请人： Patrick Andre , David R. Phillips , Charles Homcy
发明人： Patrick Andre , David R. Phillips , Charles Homcy
IPC分类号： A61F2/02
CPC分类号： A61K31/473 , A61K31/4745 , A61K31/52 , A61L27/34 , A61L27/54 , A61L29/085 , A61L29/16 , A61L2300/434
摘要： The present invention provides novel compositions and methods for inhibiting restenosis, thrombosis, and/or inflammation in a patient undergoing a vascular intervention. More particularly, the present invention provides intravascular devices coated with one or more spleen tyrosine kinase (Syk) inhibitors. Methods for inhibiting restenosis, thrombosis, and/or inflammation in a patient by treatment with such intravascular devices are also provided. In addition, the present invention provides methods for treating sickle cell disease using Syk inhibitors.
摘要翻译： 本发明提供了用于在经历血管干预的患者中抑制再狭窄，血栓形成和/或炎症的新型组合物和方法。 更具体地，本发明提供涂覆有一种或多种脾脏酪氨酸激酶（Syk）抑制剂的血管内装置。 还提供了通过用这种血管内装置治疗来抑制患者再狭窄，血栓形成和/或炎症的方法。 此外，本发明提供了使用Syk抑制剂治疗镰状细胞病的方法。
-
公开(公告)号：US08455441B2
公开(公告)日：2013-06-04
申请号：US13414499
申请日：2012-03-07
申请人： Genmin Lu , David R. Phillips , Patrick Andre , Uma Sinha
发明人： Genmin Lu , David R. Phillips , Patrick Andre , Uma Sinha
IPC分类号： A61K39/00
CPC分类号： A61K38/4846 , A61K38/00 , A61K38/4826 , A61K38/4833 , A61K38/4853 , A61K39/00 , A61K47/60 , C07K14/435 , C12N9/6432 , C12Y304/21006
摘要： The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
摘要翻译： 本发明涉及靶向因子Xa的抗凝剂的解毒剂。 解毒剂是与因子Xa抑制剂结合的因子Xa蛋白衍生物，从而基本上中和它们，但不组装到凝血酶原酶复合物中。 本文所述的衍生物缺乏或具有降低的内在凝结剂活性。 本文公开了在目前正在进行使用因子Xa抑制剂进行抗凝治疗的患者中停止或预防出血的方法。
-
-
-
-
-
-
-
-
-
搜索结果
32 条记录 (耗时 0.027 秒)
